Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.40 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 2/20 | 0.38 |
| ▸ | FDPS | P14324 | 1/20 | 0.38 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.36 |
| ▸ | ABAT | P80404 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.36 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29417672 | 1.00 | ALDH1A1 (0.43) | ALDH1A1TSHRALDH1A3AOX1SMN1; SMN2 | |
| SCHEMBL5073125 | 0.86 | ALDH1A1 (0.43) | ALDH1A1TSHRALDH1A3AOX1SMN1; SMN2 | |
| SCHEMBL16950782 | 0.82 | TRPA1 (0.36) | ALDH1A1SMN1; SMN2RAB9AAPPTDP1 | |
| SCHEMBL16962564 | 0.82 | APP (0.38) | ALDH1A1SMN1; SMN2RAB9AAPPTUBB1 | |
| SCHEMBL584601 | 0.80 | EPHX2 (0.50) | ALDH1A1TSHRAOX1SMN1; SMN2APP | |
| SCHEMBL24445666 | 0.79 | ALDH1A1 (0.61) | ALDH1A1TSHRAOX1RAB9AMAPT | |
| SCHEMBL851413 | 0.79 | ALDH1A1 (0.52) | ALDH1A1TSHRALDH1A3AOX1ALDH3A1 | |
| SCHEMBL7857195 | 0.79 | ALDH1A1 (0.43) | ALDH1A1TSHRAOX1RAB9AAPP | |
| SCHEMBL12519223 | 0.79 | ALDH1A1 (0.47) | ALDH1A1TSHRALDH1A3AOX1APP | |
| SCHEMBL15664456 | 0.79 | ALDH1A1 (0.43) | ALDH1A1TSHRAOX1RAB9AAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2026-02-12 | — | — | US | disclosed |
| US-12545659-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| EP-4584265-A1 | NOVEL COMPOUNDS, COMPOSITIONS AND THERAPEUTIC USES THEREOF | Cambridge Enterprise Limited (GB) | 2025-07-16 | — | — | EP | disclosed |
| WO-2025085564-A1 | LYSINE ACETYLTRANSFERASE INHIBITORS | Kronos Bio, Inc. (US) | 2025-04-24 | — | — | WO | disclosed |
| WO-2025085554-A1 | LYSINE ACETYLTRANSFERASE INHIBITORS | Kronos Bio, Inc. (US) | 2025-04-24 | — | — | WO | disclosed |
| US-20250121073-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| US-12150995-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-11-26 | — | — | US | disclosed |
| US-12145925-B2 | Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer | ATLASMEDX, INC. (US) | 2024-11-19 | — | — | US | disclosed |
| US-20240287060-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2024-08-29 | — | — | US | disclosed |
| WO-2024052690-A1 | NOVEL COMPOUNDS, COMPOSITIONS AND THERAPEUTIC USES THEREOF | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2024-03-14 | — | — | WO | disclosed |
| CN-1384825-A | Benzylidene-thiazolidinediones and analogues thereof and their use in the treatment of diabetes | MAXIA PHARMACEUTICALS INC (US) | 2002-12-11 | — | — | CN | disclosed |
| WO-2002072543-A2 | RXR ACTIVATING MOLECULES | MAXIA PHARMACEUTICALS, INC. (US) | 2002-09-19 | — | — | WO | disclosed |
| EP-1214304-A1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF DIABETES | Maxia Pharmaceuticals, Inc. (US) | 2002-06-19 | — | — | EP | disclosed |
| JP-2002145822-A | METHOD FOR PRODUCING FLUORINE-CONTAINING BENZALDEHYDE | BAYER AG | 2002-05-22 | — | — | JP | disclosed |
| US-20020038055-A1 | Process for preparing fluorine-containing benzaldehydes | LANXESS DEUTSCHLAND GMBH (DE) | 2002-03-28 | — | — | US | disclosed |
| EP-1191012-A1 | Process for the preparation of fluorine containing benzaldehydes | BAYER AG (DE) | 2002-03-27 | — | — | EP | disclosed |
| WO-2001016122-A1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF DIABETES | MAXIA PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
| EP-0070464-B1 | SUBSTITUTED PHENYLCYCLOPROPANECARBOXYLIC-ACID ESTERS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS INSECTICIDES | BAYER AG (DE) | 1985-10-02 | — | — | EP | disclosed |
| US-4529557-A | Fluorine substitution on phenyl ring | BAYER AKTIENGESELLSCHAFT (DE) | 1985-07-16 | — | — | US | disclosed |
| EP-0070464-A1 | Substituted phenylcyclopropanecarboxylic-acid esters, process for their preparation and their use as insecticides | BAYER AG (DE) | 1983-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545659-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK4 | ALDH1A1 4348/4885TSHR 629/4885ALDH1A3 3327/4885 |
| US-20250121073-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885TSHR 3319/4885ALDH1A3 3176/4885 |
| US-12150995-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885TSHR 3319/4885ALDH1A3 3176/4885 |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK4 | ALDH1A1 3721/4885TSHR 334/4885ALDH1A3 2933/4885 |
| US-12145925-B2 | Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer | PARP2, PARP12, PARP1 | ALDH1A1 1089/4885TSHR 4610/4885ALDH1A3 1363/4885 |
| US-20240287060-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | CSNK1A1, CSNK1D, CSNK2A1 | ALDH1A1 2913/4885TSHR 2934/4885ALDH1A3 2318/4885 |
| US-20020038055-A1 | Process for preparing fluorine-containing benzaldehydes | FLI1, FIP1L1, AFF4 | ALDH1A1 337/4885TSHR 1713/4885ALDH1A3 1360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.